Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With RHF Caused by PAH

Inclusion Criteria: * Patients who have no serious cerebrovascular, liver, kidney and lung organ and tissue diseases. * No corticosteroids or immunosuppressive agents had been administered to the - Patients in the three months prior to enrollment in the study. * Patients voluntarily participated in the study and signed an informed consent form. Exclusion Criteria: * Patients who install the circulation aids. * Patients who have been diagnosed with active myocarditis or amyloid cardiomyopathy. * Fasting blood glucose level exceeded 12.21 mmol/L in individuals with uncontrolled diabetes. * Patients who suffer from anuria, urethral strictures, stones, or tumors caused by urination disorders. * Patients with acute myocardial infarctions, persistent ventricular tachycardias, or ventricular fibrillations, and cerebrovascular accidents within the first 30 days of the screening period. * Patients with a history of allergy or specific reactions to benzodiazepines. (Mozavaputan hydrochloride, Benaepril hydrochloride) * Any of the following laboratory tests were abnormal: serum creatinine\> 2.5 times the upper normal value limit, serum sodium\> 145 mmol/L, and serum potassium\> 5.5 mmol/L. * Pregnant women, lactating women, or patients who may be pregnant or have pregnancy plans. * Patients with other contraindications to the use of tolvaptan. * Patients who have been taking tolvaptan within the first 3 months before inclusion in the study, either when the drug was marketed or when it was being clinically studied. * Additionally, patients who were judged by the investigators not fit to be enrolled in this trial.